CAR-T Therapy Space 2017 Progress Report – Nasdaq
Korea Biomedical Review |
CAR–T Therapy Space 2017 Progress Report
Nasdaq The CAR–T therapy space in particular, has been grabbing investors, courtesy of two key approvals. The FDA's approval of Novartis AG'sNVS breakthrough gene transfer treatment, Kymriah (tisagenlecleucel) suspension for the treatment of B-cell precursor … Creative Biolabs Announced Bio-distribution Analysis Services for … Clinical trials on CAR-T cell therapies surge in two years – Korea … Creative Biolabs Released A Brand New CAR–T in vivo assay Service |
